Download

    Institut für Medizinische Virologie (Institute of Medical Virology)

    2. Where is it located (include both address and geographical location)?

    Institut für Medizinische Virologie, Medizinische Fakultät, Universität Zürich, Winterthurerstrasse 190, CH-8057 Zürich, Switzerland

    N 47° 23' 52.08", E 8° 33' 01.92"

    3. Floor area of laboratory areas by containment level
    BL 3 , 25.00 SqM
    Of note, the Institute of Medical Virology holds a BSL4 license for diagnostic purposes only, as follows: “Inactivation of environmental samples and of potentially highly pathogenic viruses for diagnostic purposes within the framework of the Regional Laboratory Network”.
    Total laboratory floor area (SqM): 
    25

    4. The organizational structure of each facility

    Personnel
    (i) Total number of personnel: 
    2

    (ii) Division of personnel

    Military: 
    0
    Civilian: 
    2

    (iii) Division of personnel by category

    Scientists: 
    1
    Engineers: 
    0
    Technicians: 
    1
    Administrative and support staff: 
    0
    (iv) List the scientific disciplines represented in the scientific/engineering staff

    Microbiology (virology).

    (v) Are contractor staff working in the facility? If so, provide an approximate number.
    0
    Funding
    (vi) What is (are) the source(s) of funding for the work conducted in the facility, including indication if activity is wholly or partly financed by the Ministry of Defence?

    Cantons of Appenzell Ausserrhoden, Appenzell Innerrhoden, Glarus, Graubünden, Sankt Gallen, Schaffhausen, Thurgau, Zug, Zürich, and the Principality of Liechtenstein.

    Research
    Development
    Test & Evaluation
    Analysis / Diagnosis
    Education & Training
    Other activities

    0 %
    0 %
    10 %
    50 %
    10 %
    30 % (costs for maintenance and amortization)

    (vii) What are the funding levels for the following programme areas:

    Research: 
    0 %
    Development: 
    0 %
    Test and evaluation: 
    10 %
    (viii) Briefly describe the publication policy of the facility

    Publication in open literature.

    (ix) Provide a list of publicly-available papers and reports resulting from the work published during the previous 12 months. (To include authors, titles and full references)

    Metagenomic virome sequencing in living donor-recipient kidney transplant pairs revealed JC Polyomavirus transmission. Schreiber PW, Kufner V, Hübel K, Schmutz S, Zagordi O, Kaur A, Bayard C, Greiner M, Zbinden A, Capaul R, Böni J, Hirsch HH, Mueller TF, Mueller NJ, Trkola A, Huber M. Clin Infect Dis. 2018 Dec 2. doi: 10.1093/cid/ciy1018.

    Inferring the age difference in HIV transmission pairs by applying phylogenetic methods on the HIV transmission network of the Swiss HIV Cohort Study. Kusejko K, Kadelka C, Marzel A, Battegay M, Bernasconi E, Calmy A, Cavassini M, Hoffmann M, Böni J, Yerly S, Klimkait T, Perreau M, Rauch A, Günthard HF, Kouyos RD; Swiss HIV Cohort Study. Virus Evol. 2018 Sep 18;4(2):vey024. doi: 10.1093/ve/vey024. eCollection 2018 Jul. Review.

    Tracing HIV-1 strains that imprint broadly neutralizing antibody responses. Kouyos RD, Rusert P, Kadelka C, Huber M, Marzel A, Ebner H, Schanz M, Liechti T, Friedrich N, Braun DL, Scherrer AU, Weber J, Uhr T, Baumann NS, Leemann C, Kuster H, Chave JP, Cavassini M, Bernasconi E, Hoffmann M, Calmy A, Battegay M, Rauch A, Yerly S, Aubert V, Klimkait T, Böni J, Metzner KJ, Günthard HF, Trkola A; Swiss HIV Cohort Study. Nature. 2018 Sep;561(7723):406-410. doi: 10.1038/s41586-018-0517-0. Epub 2018 Sep 10.

    Quantifying the drivers of HIV transmission and prevention in men who have sex with men: a population model-based analysis in Switzerland. Kusejko K, Marzel A, Hampel B, Bachmann N, Nguyen H, Fehr J, Braun DL, Battegay M, Bernasconi E, Calmy A, Cavassini M, Hoffmann M, Böni J, Yerly S, Klimkait T, Perreau M, Rauch A, Günthard HF, Kouyos RD; Swiss HIV Cohort Study. HIV Med. 2018 Nov;19(10):688-697. doi: 10.1111/hiv.12660. Epub 2018 Jul 26.

    The Cumulative Impact of Harm Reduction on the Swiss HIV Epidemic: Cohort Study, Mathematical Model, and Phylogenetic Analysis. Marzel A, Kusejko K, Weber R, Bruggmann P, Rauch A, Roth JA, Bernasconi E, Calmy A, Cavassini M, Hoffmann M, Böni J, Yerly S, Klimkait T, Perreau M, Günthard HF, Kouyos RD; Swiss HIV Cohort Study . Open Forum Infect Dis. 2018 May 19;5(5):ofy078. doi: 10.1093/ofid/ofy078. eCollection 2018 May.

    Distinct, IgG1-driven antibody response landscapes demarcate individuals with broadly HIV-1 neutralizing activity. Kadelka C, Liechti T, Ebner H, Schanz M, Rusert P, Friedrich N, Stiegeler E, Braun DL, Huber M, Scherrer AU, Weber J, Uhr T, Kuster H, Misselwitz B, Cavassini M, Bernasconi E, Hoffmann M, Calmy A, Battegay M, Rauch A, Yerly S, Aubert V, Klimkait T, Böni J, Kouyos RD, Günthard HF, Trkola A; Swiss HIV Cohort Study. J Exp Med. 2018 Jun 4;215(6):1589-1608. doi: 10.1084/jem.20180246. Epub 2018 May 24.

    CD4 cell count response to first-line combination ART in HIV-2+ patients compared with HIV-1+ patients: a multinational, multicohort European study. Wittkop L, Arsandaux J, Trevino A, Schim van der Loeff M, Anderson J, van Sighem A, Böni J, Brun-Vezinet F, Soriano V, Boufassa F, Brockmeyer N, Calmy A, Dabis F, Jarrin I, Dorrucci M, Duque V, Fätkenheuer G, Zangerle R, Ferrer E, Porter K, Judd A, Sipsas NV, Lambotte O, Shepherd L, Leport C, Morrison C, Mussini C, Obel N, Ruelle J, Schwarze-Zander C, Sonnerborg A, Teira R, Torti C, Valadas E, Colin C, Friis-Møller N, Costagliola D, Thiebaut R, Chene G, Matheron S; COHERE in EuroCoord and ACHIeV2e Study Group. J Antimicrob Chemother. 2017 Oct 1;72(10):2869-2878. doi: 10.1093/jac/dkx210.

    Dissecting HIV Virulence: Heritability of Setpoint Viral Load, CD4+ T-Cell Decline, and Per-Parasite Pathogenicity. Bertels F, Marzel A, Leventhal G, Mitov V, Fellay J, Günthard HF, Böni J, Yerly S, Klimkait T, Aubert V, Battegay M, Rauch A, Cavassini M, Calmy A, Bernasconi E, Schmid P, Scherrer AU, Müller V, Bonhoeffer S, Kouyos R, Regoes RR; Swiss HIV Cohort Study. Mol Biol Evol. 2018 Jan 1;35(1):27-37. doi: 10.1093/molbev/msx246.

    Notes
    N/A
    Attachments
    N/A
    5. Briefly describe the biological defence work carried out at the facility, including type(s) of micro-organisms(9) and/or toxins studied, as well as outdoor studies of biological aerosols.

    The Institute of Medical Virology at the University of Zurich is the Regional Competence Center for the primary analysis of viral samples suspicious of a bioterror-related background. This represents an additional and not a continuous task of the viral diagnostics laboratory.

    For further information please visit:
    https://www.virology.uzh.ch/index_en.html

    (9) Including viruses and prions.

    Report Index